Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease

Journal of Cellular and Molecular Medicine

Volumn 8, Issue 3, 2004, Pages 317-328

  Kountouras, Jannis ^a,b   Zavos, Christos ^a   Chatzopoulos, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Department of Medicine ^*  (Greece)

Author keywords

Crohn's; Cyclosporine; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CYCLOSPORIN; IMMUNOLOGIC FACTOR;

CROHN DISEASE; DRUG EFFECT; ENTERITIS; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; MUCOSAL IMMUNITY; REVIEW; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA;

EID: 20044389090     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2004.tb00321.x     Document Type: Review

References (40)

1. Abreu M.T., Arditi M., Innate immunity and toll-like receptors: clinical implications of basic science research, J. Pediatr., 144: 421-429, 2004
2. Baert F., Rutgeerts P., Immunomodulator therapy of inflammatory bowel disease, Acta Clin. Belg., 52: 251-257, 1997
3. Panes J., Granger D.N., Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease, Gastroenterology, 114: 1066-1090, 1998
4. Kountouras J., Chatzopoulos D., Zavos C., Reactive oxygen metabolites and upper gastrointestinal diseases, Hepatogastroenterology, 48: 743-751, 2001
5. Fiocchi C., Inflammatory bowel disease: etiology and pathogenesis, Gastroenterology, 115: 182-205, 1998
6. th Edn, Philadelphia: Saunders, pp. 2005-2038, 2002
7. Sandborn W.J., Tremaine W.J., Cyclosporine treatment of inflammatory bowel disease, Mayo Clin. Proc., 67: 981-990, 1992
8. Sandborn W.J., A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate, Am. J. Gastroenterol., 91: 423-433, 1996
9. Aranda R., Morgan K., Immunosuppressive drugs in the treatment of inflammatory bowel disease, Semin. Gastrointest. Dis., 9: 2-9, 1998
10. Van Assche G., D'Haens G., Noman M., Vermeire S., Hiele M., Asnong K., Arts J., D'Hoore A., Penninckx F., Rutgeerts P., Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology, 125: 1025-1031, 2003
11. Van Assche G., Dalle I., Noman M., Aerden I., Swijsen C., Asnong K., Macs B., Ceuppens J., Geboes K., Rutgeerts P., A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis, Am. J. Gastroenterol., 98: 369-376, 2003
12. Ying S., Khan L.N., Meng Q., Barnes N.C., Kay A.B., Cyclosporin A, apoptosis of BALT cells and expression of Bcl-2 in asthmatics, Eur. Respir. J., 22: 207-212, 2003
13. Koenen H.J., Michielsen E.C., Verstappen J., Fasse E., Joosten I., Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis, Transplantation, 75: 1581-1590, 2003
14. Kountouras J., Kouklakis G., Zavos C., Chatzopoulos D., Moschos J., Molyvas E., Zavos N., Apoptosis, inflammatory bowel disease and carcinogenesis: overview of international and Greek experiences, Can. J. Gastroenterol., 17: 249-258, 2003
15. Aiko S., Conner E.M., Fuseler J.A., Grisham M.B., Effects of cyclosporine or FK506 in chronic colitis, J. Pharmacol. Exp. Ther., 280: 1075-1084, 1997
16. Rafiee P., Johnson C.P., Li M.S., Ogawa H., Heidemann J., Fisher P.J., Lamirand T.H., Otterson M.F., Wilson K.T., Binion D.G., Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium, J. Biol. Chem., 277: 35605-35615, 2002
17. Brynskov J., Tvede N., Andersen C.B., Vilien M., Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease, Gut, 33: 55-58, 1992
18. Metcalf D., The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors, Blood, 67: 257-267, 1986
19. Pullman W.E., Elsbury S., Kobayashi M., Hapel A.J., Doe W.F., Enhanced mucosal cytokine production in inflammatory bowel disease, Gastroenterology, 102: 529-537, 1992
20. Breese E., Braegger C.P., Corrigan C.J., Walker-Smith J.A., MacDonald T.T., Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa, Immunology, 78: 127-131, 1993
21. Montelcone G, Biancone L., Marasco R., Morrone G., Marasco O., Luzza F., Pallone F., Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells, Gastroenterology, 112: 1169-1178, 1997
22. Bretscher P.A., Havele C., Cyclosporin A can switch the immune response induced by antigen from a humoral to a cell-mediated mode, Eur. J. Immunol., 22: 349-355, 1992
23. Neurath M.F., Finotto S., Fuss I., Boirivant M., Galle P.R., Strober W., Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question, Trends Immunol., 22: 21-26, 2001
24. Bernstein C.N., Shanahan F., Cyclosporine and inflammatory bowel disease: still more questions, Gastroenterology, 108: 943-945, 1995
25. Egan L.J., Sandborn W.J., Tremaine W.J., Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine, Am. J. Gastroenterol, 93: 442-448, 1998
26. Boura P., Kountouras J., Papadopoulou A., Zaharioudaki E., Anastasiadis N., Tsakiri I., Tsapas G., Peripheral blood and colonic T cell subsets and HLA-DR expression before and after low dose cyclosporine treatment in patients with ulcerative colitis, Allergy Proceedings, 9: 324, 1988
27. Sandborn W.J., Tremaine W.J., Lawson G.M., Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine, Am. J. Gastroenterol., 91: 37-43, 1996
28. Stange E.F., Modigliani R., Pena A.S., Wood A.J., Feutren G., Smith P.R., European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group, Gastroenterology, 109: 774-782, 1995
29. Loftus C.G., Loftus E.V. Jr., Sandborn W.J., Cyclosporin for refractory ulcerative colitis, Gut, 52: 172-173, 2003
30. Navazo L., Salata H., Morales S., Dorta M.C., Perez F., de las Casas D., Aviles J., Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis, Scand. J. Gastroenterol, 36: 610-614, 2001
31. Rolny P., Sadik R., Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy, Int. J. Colorectal Dis., 17: 67-69, 2002
32. Okamura S., Aoki H., Ohashi S., Urano F., Shimodaira M., Kanamori S., Ishikawa H., Segawa K., Efficacy of cyclosporine with corticotropin for refractory ulcerative colitis, Hepatogastroenterology, 50: 91-94, 2003
33. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., Michelassi F., Hanauer S., Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N. Engl. J. Med., 330: 1841-1845, 1994
34. D'Haens G., Lemmens L., Geboes K., Vandeputte L., Van Acker F., Mortelmans L., Peeters M., Vermeire S., Penninekx F., Nevens F., Hiele M., Rutgeerts P., Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, Gastroenterology, 120: 1323-1329, 2001
35. Hawthorne A.B., Cyclosporin and refractory colitis, Eur. J. Gastroenterol. Hepatol., 15: 239-244, 2003
36. Banic M., Anic B., Brkic T., Ljubicic N., Plesko S., Dohoczky C., Erceg D., Petrovecki M., Stipancic I., Rotkvic I., Effect of cyclosporine in a murine model of experimental colitis, Dig. Dis. Sci., 47: 1362-1368, 2002
37. th Edn, Philadelphia: Saunders, pp. 473-486, 2002
38. Kountouras J., Zavos C., Chatzopoulos D., Apoptosis and apoptosis-related proteins in inflammatory bowel disease, Apoptosis, 9: 657-658, 2004
39. Morisaki T., Matsunaga H., Beppu K., Ihara E., Hirano K., Kanaide H., Mori M., Katano M., A combination of cyclosporine-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells, Anticancer Res., 20: 3363-3373, 2000
40. Lim S.J., Simeone A.M., Kim C.K., Tari A.M., Cyclosporine A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells, Int. J. Cancer, 101: 243-247, 2002